These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25777345)

  • 1. Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.
    Rao A; Lauer R
    Oncologist; 2015 Apr; 20(4):370-1. PubMed ID: 25777345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
    Zhang HL; Qin XJ; Wang HK; Gu WJ; Ma CG; Shi GH; Zhou LP; Ye DW
    Oncotarget; 2015 Nov; 6(34):36870-83. PubMed ID: 26472104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
    Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
    Levy A; Menard J; Albiges L; Loriot Y; Di Palma M; Fizazi K; Escudier B
    Eur J Cancer; 2013 May; 49(8):1898-904. PubMed ID: 23490648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
    Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
    J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential sorafenib and sunitinib for renal cell carcinoma.
    Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
    J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
    Araki H; Tsuzuki T; Kimura T; Tanaka K; Yamada S; Sassa N; Yoshino Y; Hattori R; Gotoh M
    Am J Clin Pathol; 2015 Apr; 143(4):492-9. PubMed ID: 25780000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
    Hainsworth JD; Waterhouse DM; Penley WC; Shipley DL; Thompson DS; Webb CD; Anthony Greco F
    Cancer Invest; 2013 Jun; 31(5):323-9. PubMed ID: 23614653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
    Procopio G; Verzoni E; Bracarda S; Ricci S; Sacco C; Ridolfi L; Porta C; Miceli R; Zilembo N; Bajetta E;
    Ann Oncol; 2013 Dec; 24(12):2967-71. PubMed ID: 24063860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
    Ryan CW; Goldman BH; Lara PN; Mack PC; Beer TM; Tangen CM; Lemmon D; Pan CX; Drabkin HA; Crawford ED;
    J Clin Oncol; 2007 Aug; 25(22):3296-301. PubMed ID: 17664477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
    Yardley DA; Dickson N; Drosick D; Earwood C; Inhorn R; Murphy P; Hainsworth JD
    Clin Breast Cancer; 2016 Jun; 16(3):180-7. PubMed ID: 26943991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
    Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
    Sullivan RJ; Ibrahim N; Lawrence DP; Aldridge J; Giobbie-Hurder A; Hodi FS; Flaherty KT; Conley C; Mier JW; Atkins MB; McDermott DF
    Oncologist; 2015 Jun; 20(6):617-8. PubMed ID: 25986244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.